semaglutide pharmacokinetics For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg A phase 1, randomized, double‐blind,

Here's how to set yourself up for success

In this post, I take a deep dive into EVOKE and EVOKE+, examining trial design, endpoints, effect sizes, and interpretability

The Therapeutic Goods Administration (TGA) in Australia has been working with Novo Nordisk, pharmaceutical wholesalers and organisations representing health professionals and patient groups to manage the current shortage

Lillys tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1

And sometimes, improving your health opens the door to opportunities you never expected

GLP-1 drugs are indicated for patients with BMI above 25 even without complications, or BMI above 23 with obesity-related conditions such as diabetes, hypertension, or fatty liver disease